Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6511
    -0.0008 (-0.12%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    107,318.25
    -853.43 (-0.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6041
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0902
    -0.0000 (-0.00%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     

Micron, CarMax and Tyson Foods fall premarket; MillerKnoll rises

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Thursday, December 22nd. Please refresh for updates.

Micron (NASDAQ:MU) stock fell 3.9% after the chipmaker forecast a much steeper-than-expected second-quarter loss and said it will lay off 10% of its workforce next year.

CarMax (NYSE:KMX) stock slumped 12.6% following the auto retailer pausing share buybacks after reporting an 86% fall in quarterly profit, hurt by waning demand for used cars.

Airbnb (NASDAQ:ABNB) stock rose 0.5% despite the European Union’s top court ruled the accommodation provider must provide information in rental contracts to tax authorities as well as withhold tax.

ADVERTISEMENT

Under Armour (NYSE:UAA) stock rose 0.2% after the athletic apparel retailer named Stephanie Linnartz, currently president at Marriott International (NASDAQ:MAR), up 0.2%, as its next CEO.

Tyson Foods (NYSE:TSN) stock fell 0.6% after the Wall Street Journal reported that the meat supplier plans to consolidate its corporate offices, resulting in hundreds of job losses.

Mirati Therapeutics (NASDAQ:MRTX) stock rose 6.6% after the FDA granted the drugmaker's colorectal cancer treatment a “breakthrough therapy” designation. MillerKnoll (NASDAQ:MLKN) stock rose 3.2% after the furniture company reported better-than-expected quarterly results, making up for a 13% decline in orders with higher prices.

Related Articles

Micron, CarMax and Tyson Foods fall premarket; MillerKnoll rises

YouTube, NFL strike deal to stream Sunday Ticket package of games

AMC to raise $110 million, proposes reverse stock split